Poor choice of primary outcome in a clinical trial of pirfenidone in patients with IPF.

Suppr

超能文献

作者信息

Levitt Joseph, Gould Michael K

出版信息

Am J Respir Crit Care Med. 2005 Nov 1;172(9):1228-9; author reply 1229. doi: 10.1164/ajrccm.172.9.951.

DOI:10.1164/ajrccm.172.9.951

PMID:16249322

Abstract

摘要

相似文献

Poor choice of primary outcome in a clinical trial of pirfenidone in patients with IPF.

Am J Respir Crit Care Med. 2005 Nov 1;172(9):1228-9; author reply 1229. doi: 10.1164/ajrccm.172.9.951.

The questionable efficacy of pirfenidone in IPF.

Am J Respir Crit Care Med. 2005 Nov 1;172(9):1228. doi: 10.1164/ajrccm.172.9.950.

Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis.

Am J Respir Crit Care Med. 2005 May 1;171(9):1040-7. doi: 10.1164/rccm.200404-571OC. Epub 2005 Jan 21.

[Idiopathic pulmonary fibrosis -- progress in sight].

Duodecim. 2011;127(24):2639-45.

Pirfenidone for the treatment of idiopathic pulmonary fibrosis.

Expert Rev Respir Med. 2014 Oct;8(5):539-45. doi: 10.1586/17476348.2014.915750. Epub 2014 Aug 12.

Is idiopathic pulmonary fibrosis now treatable?

Am J Respir Crit Care Med. 2005 May 1;171(9):939-40. doi: 10.1164/rccm.2502001.

The evolving pharmacotherapy of pulmonary fibrosis.

Expert Opin Pharmacother. 2013 Jan;14(1):79-89. doi: 10.1517/14656566.2013.758250.

Pirfenidone: a novel agent for the treatment of idiopathic pulmonary fibrosis.

Ann Pharmacother. 2013 Mar;47(3):361-7. doi: 10.1345/aph.1R337. Epub 2013 Feb 12.

Open-label compassionate use one year-treatment with pirfenidone to patients with chronic pulmonary fibrosis.

Intern Med. 2002 Dec;41(12):1118-23. doi: 10.2169/internalmedicine.41.1118.

Pirfenidone treatment of idiopathic pulmonary fibrosis.

Ther Adv Respir Dis. 2012 Apr;6(2):107-14. doi: 10.1177/1753465812436663. Epub 2012 Feb 14.

引用本文的文献

Pirfenidone treatment of idiopathic pulmonary fibrosis.

Ther Clin Risk Manag. 2011 Feb 8;7:39-47. doi: 10.2147/TCRM.S12209.

Targeted therapy for systemic sclerosis: how close are we?

Nat Rev Rheumatol. 2010 May;6(5):269-78. doi: 10.1038/nrrheum.2010.48. Epub 2010 Apr 13.

Pirfenidone modulates airway responsiveness, inflammation, and remodeling after repeated challenge.

Am J Respir Cell Mol Biol. 2006 Sep;35(3):366-77. doi: 10.1165/rcmb.2005-0452OC. Epub 2006 May 4.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Poor choice of primary outcome in a clinical trial of pirfenidone in patients with IPF.

Am J Respir Crit Care Med. 2005 Nov 1;172(9):1228-9; author reply 1229. doi: 10.1164/ajrccm.172.9.951.

The questionable efficacy of pirfenidone in IPF.

Am J Respir Crit Care Med. 2005 Nov 1;172(9):1228. doi: 10.1164/ajrccm.172.9.950.

Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis.

Am J Respir Crit Care Med. 2005 May 1;171(9):1040-7. doi: 10.1164/rccm.200404-571OC. Epub 2005 Jan 21.

[Idiopathic pulmonary fibrosis -- progress in sight].

Duodecim. 2011;127(24):2639-45.

Pirfenidone for the treatment of idiopathic pulmonary fibrosis.

Expert Rev Respir Med. 2014 Oct;8(5):539-45. doi: 10.1586/17476348.2014.915750. Epub 2014 Aug 12.

Is idiopathic pulmonary fibrosis now treatable?

Am J Respir Crit Care Med. 2005 May 1;171(9):939-40. doi: 10.1164/rccm.2502001.

The evolving pharmacotherapy of pulmonary fibrosis.

Expert Opin Pharmacother. 2013 Jan;14(1):79-89. doi: 10.1517/14656566.2013.758250.

Pirfenidone: a novel agent for the treatment of idiopathic pulmonary fibrosis.

Ann Pharmacother. 2013 Mar;47(3):361-7. doi: 10.1345/aph.1R337. Epub 2013 Feb 12.

Open-label compassionate use one year-treatment with pirfenidone to patients with chronic pulmonary fibrosis.

Intern Med. 2002 Dec;41(12):1118-23. doi: 10.2169/internalmedicine.41.1118.

Pirfenidone treatment of idiopathic pulmonary fibrosis.

Ther Adv Respir Dis. 2012 Apr;6(2):107-14. doi: 10.1177/1753465812436663. Epub 2012 Feb 14.

引用本文的文献

Pirfenidone treatment of idiopathic pulmonary fibrosis.

Ther Clin Risk Manag. 2011 Feb 8;7:39-47. doi: 10.2147/TCRM.S12209.

Targeted therapy for systemic sclerosis: how close are we?

Nat Rev Rheumatol. 2010 May;6(5):269-78. doi: 10.1038/nrrheum.2010.48. Epub 2010 Apr 13.

Pirfenidone modulates airway responsiveness, inflammation, and remodeling after repeated challenge.

Am J Respir Cell Mol Biol. 2006 Sep;35(3):366-77. doi: 10.1165/rcmb.2005-0452OC. Epub 2006 May 4.